IMV Балансовая стоимость акции
Что обозначает Балансовая стоимость акции в IMV?
Балансовая стоимость акции IMV, Inc. является -0.40
Какое определение для Балансовая стоимость акции?
Балансовая стоимость на акцию - это активы компании за вычетом обязательств, разделенные на количество акций в обращении.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Балансовая стоимость акции компаний в Health Care сектор на TSX по сравнению с IMV
Что делает IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Компании с балансовая стоимость акции похож на IMV
- MediaAlpha имеет Балансовая стоимость акции из -0.40
- Conyers Park Acquisition имеет Балансовая стоимость акции из -0.40
- Sino International имеет Балансовая стоимость акции из -0.40
- Sports Ventures Acquisition имеет Балансовая стоимость акции из -0.40
- SearchGuy.com имеет Балансовая стоимость акции из -0.40
- Molecular Data Inc имеет Балансовая стоимость акции из -0.40
- IMV имеет Балансовая стоимость акции из -0.40
- Inventiva S.A имеет Балансовая стоимость акции из -0.40
- OptiNose Inc имеет Балансовая стоимость акции из -0.39
- Venus Concept имеет Балансовая стоимость акции из -0.39
- ParkerVision имеет Балансовая стоимость акции из -0.39
- Hua Lien International () имеет Балансовая стоимость акции из -0.39
- Phunware Inc имеет Балансовая стоимость акции из -0.39